Table 3.
Correlation analyses of the serum levels of adiponectin with the serum levels of lipids and apoB in total VLDL and the VLDL subclasses, performed separately for HVs and patients with MS.
| Adiponectin (µg/mL) | ||||
|---|---|---|---|---|
| HV (N = 65) |
MS (N = 65) |
|||
| Variable (mg/dL) | r | p | r | p |
| VLDL-C | −0.44 | 0.0003 | −0.15 | 0.2406 |
| VLDL1-C | −0.44 | 0.0002 | −0.18 | 0.1565 |
| VLDL2-C | −0.42 | 0.0005 | −0.16 | 0.2099 |
| VLDL3-C | −0.45 | 0.0002 | −0.15 | 0.2334 |
| VLDL4-C | −0.37 | 0.0021 | −0.09 | 0.4980 |
| VLDL5-C | 0.02 | 0.8480 | 0.19 | 0.1281 |
| VLDL-FC | −0.44 | 0.0003 | −0.15 | 0.2456 |
| VLDL1-FC | −0.52 | <0.0001 | −0.22 | 0.0724 |
| VLDL2-FC | −0.44 | 0.0002 | −0.21 | 0.0932 |
| VLDL3-FC | −0.43 | 0.0004 | −0.19 | 0.1381 |
| VLDL4-FC | −0.37 | 0.0025 | −0.08 | 0.5392 |
| VLDL5-FC | 0.02 | 0.8595 | −0.02 | 0.8983 |
| VLDL-TG | −0.51 | <0.0001 | −0.23 | 0.0625 |
| VLDL1-TG | −0.53 | <0.0001 | −0.27 | 0.0305 |
| VLDL2-TG | −0.48 | 0.0001 | −0.21 | 0.0957 |
| VLDL3-TG | −0.44 | 0.0003 | −0.18 | 0.1401 |
| VLDL4-TG | −0.40 | 0.0010 | −0.17 | 0.1778 |
| VLDL5-TG | 0.03 | 0.8010 | 0.05 | 0.6917 |
| VLDL-PL | −0.47 | 0.0001 | −0.22 | 0.0847 |
| VLDL1-PL | −0.55 | <0.0001 | −0.26 | 0.0335 |
| VLDL2-PL | −0.49 | <0.0001 | −0.22 | 0.0778 |
| VLDL3-PL | −0.45 | 0.0001 | −0.21 | 0.0942 |
| VLDL4-PL | −0.42 | 0.0005 | −0.14 | 0.2809 |
| VLDL5-PL | −0.10 | 0.4176 | 0.07 | 0.5612 |
| VLDL-apoB | −0.44 | 0.0002 | −0.18 | 0.1623 |
Spearman’s correlation analyses were used to evaluate the associations of the serum levels of adiponectin with the serum levels of VLDL. p-values < 0.0005 are considered statistically significant after Bonferroni correction for multiple testing and are depicted in bold. apoB, apolipoprotein B; C, cholesterol; FC, free cholesterol; HV, healthy volunteer; MS, metabolic syndrome patient; PL, phospholipid; r, Spearman’s correlation coefficient; TG, triglyceride, VLDL, very-low-density lipoprotein.